Preparation, Optimization and In-Vitro Evaluation of Curcumin-Loaded Niosome@calcium Alginate Nanocarrier as a New Approach for Breast Cancer Treatment

Biology

Mona Shayan¹  Samaneh Saffar¹  Mahsa Bourbour²  Hassan Noorbazargan³  Maryam Moghtaderi⁴  Iman Akbarzadeh⁵  FatenEshrati Yeganeh⁶  Mohammadreza Tahriri⁷ 

[1] Core Facility Center, Pasteur Institute of Iran, Tehran 1316943551, Iran;Department of Biotechnology, Alzahra University, Tehran 1993893973, Iran;Department of Biotechnology, School of Advanced Technologies in Medicine, Shahid Beheshti University of Medical Sciences, Tehran 1985717443, Iran;Department of Chemical Engineering, Faculty of Engineering, University of Tehran, Tehran 141556619, Iran;Department of Chemical and Petrochemical Engineering, Sharif University of Technology, Tehran 145888-9694, Iran;Department of Chemistry, Science and Research Branch, Islamic Azad University, Tehran 1477893855, Iran;Department of Engineering, Norfolk state University, Norfolk, VA 23504, USA;

关键词: Niosome;    Calcium alginate;    Curcumin;    Breast cancer;    Anticancer;   

DOI  :  10.3390/biology10030173

来源: DOAJ

【 摘 要 】

Cancer is one of the most common causes of mortality, and its various treatment methods can have many challenges for patients. As one of the most widely used cancer treatments, chemotherapy may result in diverse side effects. The lack of targeted drug delivery to tumor tissues can raise the possibility of damage to healthy tissues, with attendant dysfunction. In the present study, an optimum formulation of curcumin-loaded niosomes with a calcium alginate shell (AL-NioC) was developed and optimized by a three-level Box–Behnken design—in terms of dimension and drug loading efficiency. The niosomes were characterized by transmission electron microscopy, Fourier-transform infrared spectroscopy, and dynamic light scattering. The as-formulated niosomes showed excellent stability for up to 1 month at 4 °C. Additionally, the niosomal formulation demonstrated a pH-dependent release; a slow-release profile in physiological pH (7.4), and a more significant release rate at acidic conditions (pH = 3). Cytotoxicity studies showed high compatibility of AL-NioC toward normal MCF10A cells, while significant toxicity was observed in MDA-MB-231 and SKBR3 breast cancer cells. Gene expression studies of the cancer cells showed downregulation of Bcl2, cyclin D, and cyclin E genes, as well as upregulation of P53, Bax, caspase-3, and caspase-9 genes expression following the designed treatment. Flow cytometry studies confirmed a significant enhancement in the apoptosis rate in the presence of AL-NioC in both MDA-MB-231 and SKBR3 cells as compared to other samples. In general, the results of this study demonstrated that—thanks to its biocompatibility toward normal cells—the AL-NioC formulation can efficiently deliver hydrophobic drugs to target cancer cells while reducing side effects.

【 授权许可】

Unknown